MMprofiler with SKY92 Combined with ISS to Identify Risk Status in Multiple Myeloma
Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Saad Z. Usmani, MD, Chief of the Plasma Cell Disorders Program, Levine Cancer Institute/Carolinas HealthCare System, discusses the MMprofiler in multiple myeloma.
Gene expression profiling has been studied in the prognostication of multiple myeloma for over a decade, Usmani says. Now, different tools are making their way to the clinical setting, one of which is the MMprofiler.
Findings of the VTD arm of the phase III Gimema-MMY-3006 study were presented at the 2017 ASH Annual Meeting. This study investigated the MMprofiler with SKY92 combined with ISS to identify high- and low-risk patients with multiple myeloma.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
